loncastuximab tesirine

Home
Ligands
loncastuximab tesirine

GtoPdb Ligand ID: 11521

Synonyms: ADCT-402 | ADCT402 | loncastuximab tesirine-lpyl | RB4v1.2-SG-3249 | Zynlonta®

loncastuximab tesirine is an approved drug (FDA (2021), EMA (2022))

Comment: Loncastuximab tesirine (ADCT-402) is an antibody-drug conjugate that delivers the toxic payload teserine (pyrrolobenzodiazepine dimer SG3249, which acts as a DNA alkylating and cross-linking agent [3]) to CD19-expressing B cells [4].

No information available.

No information available.

Summary of Clinical Use
Loncastuximab tesirine was advenced to clinical evaluation for B cell malignancies [1-2]. IT was approved by the FDA in April 2021 (via the accelerated approval route), as a therapy for previously treated relapsed or refractory large B-cell lymphoma.

Summary of Clinical Use

Loncastuximab tesirine was advenced to clinical evaluation for B cell malignancies [1-2]. IT was approved by the FDA in April 2021 (via the accelerated approval route), as a therapy for previously treated relapsed or refractory large B-cell lymphoma.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT02669017	Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)	Phase 1 Interventional	ADC Therapeutics S.A.		1